Thursday, March 23, 2023
Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on SPID®-Technology, with Hovione’s product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, Hovione will establish the Laxxon Medical 3D screen printing technology at Hovione’s cGMP production sites first in Portugal and later in the USA.
This partnership will create an opportunity for the pharmaceutical industry to develop and manufacture clinical materials and secure industrial scale production under cGMP with Hovione, using Laxxon Medical’s 3D screen printing technology. With this partnership the platform will be available from early development phases to routine commercial manufacturing.
The 3D technology displays numerous advantages including the potential to produce unique or customised dosage forms with characteristics that cannot be achieved with conventional dosage forms, the ability to create tablets of any shape and size, the option to easily adjust the number of active substances and individual components in the composition of the tablet and even to set the dosage individually for each patient for personalised medicines.
